Krilogy Financial’s Vanda Pharmaceuticals VNDA Stock Holding History

Krilogy Financial’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-100	Closed	-$2K	–	662
2018 Q3	$2K	Buy	+100	New	+$2.04K	﹤0.01%	749
2017 Q3	–	Sell	-200	Closed	-$3K	–	848
2017 Q2	$3K	Hold	200	–	–	﹤0.01%	649
2017 Q1	$3K	Hold	200	–	–	﹤0.01%	635
2016 Q4	$3K	Buy	200 +100	+100%	+$1.61K	﹤0.01%	635
2016 Q3	$2K	Sell	100 -200	-67%	-$2.69K	﹤0.01%	677
2016 Q2	$3K	Hold	300	–	–	﹤0.01%	665
2016 Q1	$3K	Buy	+300	New	+$2.46K	﹤0.01%	589
2015 Q4	–	Sell	-300	Closed	-$3K	–	602
2015 Q3	$3K	Buy	+300	New	+$3.67K	﹤0.01%	524

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Krilogy Financial's VNDA Position: Q4 2018 in Review

Krilogy Financial sold out of Vanda Pharmaceuticals (VNDA) in Q4 2018, closing a stake of 100 shares — an estimated $2K sold.

Krilogy Financial first reported a position in VNDA in Q3 2015 and held it in 8 quarters. The position peaked at $3K in Q2 2017. 186 funds tracked by Wall St. Rank hold VNDA as of Q4 2018.

Krilogy Financial reported no remaining Vanda Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Krilogy Financial sold 100 Vanda Pharmaceuticals shares in Q4 2018, an estimated $2K.
Krilogy Financial first reported a position in Vanda Pharmaceuticals in Q3 2015 and held it in 8 quarters.
Krilogy Financial's Vanda Pharmaceuticals position peaked at $3K in Q2 2017.
186 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2018.

Based on Krilogy Financial's 13F filing for Q4 2018, filed 14 Feb 2019.